Navigation Links
JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
Date:8/24/2009

Manipulating the functions of melanosomes--the organelles in pigment-producing cells--may enhance the activity of anticancer drugs used against melanoma, according to a new study published online August 24 in the Journal of the National Cancer Institute.

To examine the role of melanosomes in the sensitivity of malignant melanoma to chemotherapeutic agents, Kevin Chen, Ph.D., Vincent Hearing, Ph.D., Michael M. Gottesman, M.D., of the Laboratory of Cell Biology at the National Cancer Institute in Bethesda, Md., and colleagues compared pigmentation and melanosome developmental stage, number, and cellular structures in melanoma cell lines in response to treatment with chemotherapeutic agents.

The authors found that late-stage melanosomes that were damaged and thus could not trap metabolites were toxic to melanoma cells. They also found that melanoma cells that survived cisplatin treatment had more stage II-III functional melanosomesalso known as early melansomes because they have not initiated melanin synthesisthan untreated melanoma cells. In addition, when melanosomes were reverted to relatively early stages, the melanoma cells became more resistant to cisplatin.

"We believe that manipulation of melanosome status either by cytotoxic or by noncytotoxic drugs opens therapeutic avenues and raises the prospect of successfully treating pigment-producing cell-related diseases and, in particular, highly intractable malignant melanomas," the authors write.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
2. JNCI news brief: High serum insulin levels and risk of prostate cancer
3. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
6. JNCI news brief: Improving the biomarker pipeline for early cancer detection
7. In brief: New prognostic indicator for patients with IPF
8. MicroDynamics to Introduce New Microscope at Quality Expo
9. CardioDynamics Shareholders Approve Merger Agreement with SonoSite
10. CardioDynamics Reports Second Fiscal Quarter 2009 Results
11. General Dynamics Awarded $9 Million Contract for U.S. Army Medical Command Lean Six Sigma Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: